MK-3475, Merck

Drug: MK-3475 (pembrolizumab)
Company: Merck & Co.
Phase: Filed
Class: Anti-programmed death-1 (PD-1) MAb
2020 sales: $4.06 billion
Net present value: $16.7 billion

Don't count out Merck ($MRK), though. When Roger Perlmutter came in as the new R&D chief, he was forced to set in motion a major R&D restructuring to account for the lengthy dry spell at the well for new approvals. MK-3475, now dubbed pembrolizumab, changed the narrative back to the company's research potential. After executing a slow series of pratfalls on largely second-tier drugs, R&D is now betting heavily that its top contender can deliver a years-long feast of new revenues. This is a drug with major partnering potential, as a whole slate of combo studies now on the drawing board attest to. As a result of their success, the R&D budget is now expected to climb in the second half of this year. 

For more:
Merck takes to Europe with its promising PD-1 cancer drug
Merck steps up with more positive data on immuno-oncology star pembrolizumab
Merck's hot immuno-oncology prospect MK-3475 grabs clear lead in blockbuster race


Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.